The immediate trigger for the correspondence is a randomized, single-blind trial by Millot and colleagues, published in the same journal, that evaluated a strategy using multiplex PCR for targeted antibiotic therapy in patients with suspected ventilator-associated pneumonia or hospital-acquired pneumonia requiring mechanical ventilation. The trial is one of the most direct tests to date of whether syndromic molecular panels can change what clinicians actually prescribe. Its findings, alongside earlier randomized data, form the backdrop against which the Reims team frames its argument about the gap between diagnostic speed and therapeutic action.

The technical logic behind multiplex PCR panels is straightforward. Platforms such as the FilmArray Pneumonia Panel extract nucleic acids from endotracheal aspirates or bronchoalveolar lavage fluid and amplify targets for a broad battery of bacterial and viral pathogens, together with key resistance determinants. Compared with conventional culture, which requires 24 to 72 hours before organisms can be identified and susceptibility tested, the molecular route delivers a pathogen profile within about an hour of sample processing. In principle, this should allow intensivists to narrow empirically broad regimens earlier, escalate when unexpected pathogens appear, or stop antibiotics altogether when no bacterial target is detected.

Randomized evidence, however, has painted a more nuanced picture. The Poole and colleagues trial published in the Journal of Infection in 2022 showed that molecular point-of-care testing for lower respiratory tract pathogens improved safe antibiotic de-escalation in ICU patients with pneumonia, a genuine stewardship gain. More recently, the INHALE WP3 trial, a multicentre, open-label, pragmatic randomized controlled trial led by Enne and colleagues and published in Intensive Care Medicine in 2025, assessed the impact of rapid, ICU-based, syndromic PCR against standard-of-care on antibiotic stewardship and clinical outcomes in hospital-acquired and ventilator-associated pneumonia. That study found effects on antibiotic use that were real but modest, and it did not translate into the kind of dramatic clinical improvements that the technology’s advocates had hoped for.

The central paradox highlighted by Goury and colleagues is that the speed of a diagnostic result is meaningless unless it is embedded in a workflow that converts information into action. A PCR result that lands in the electronic medical record at three in the morning, or that reaches a covering physician without clear guidance on how to interpret it, may simply sit unread until the morning round, by which point the theoretical time advantage has evaporated. The correspondence argues that the bottleneck in ventilator-associated pneumonia management is not analytical turnaround time but the human and organizational steps that follow: result notification, interpretation, and the willingness of clinicians to act on molecular data in the absence of conventional culture and susceptibility confirmation.

Interpretation itself is far from trivial. Multiplex panels detect nucleic acids, not necessarily viable, disease-causing organisms, so positive results must be weighed against colonization, which is extremely common in mechanically ventilated patients. Quantitative thresholds offered by some panels attempt to distinguish infection from colonization, but their performance in the critically ill population remains imperfect. Conversely, a negative panel does not exclude all pathogens, because the panels cover a defined target list. Berteau and colleagues, in a retrospective multicentre analysis published in Annals of Intensive Care in 2025, examined the epidemiology and prediction of bacteria not targeted by the FilmArray Pneumonia Plus panel in culture-positive ventilator-associated pneumonia, underscoring that a meaningful fraction of causative organisms can fall outside the panel’s detection range. Clinicians who understand these limitations may reasonably hesitate to de-escalate on the basis of a single molecular result.

Resistance gene detection adds another layer of complexity. Panels report markers such as those associated with methicillin resistance in staphylococci or extended-spectrum beta-lactamase production in enterobacterales, but the genotype-phenotype relationship is incomplete. A negative resistance result does not guarantee susceptibility to narrower agents, particularly in organisms with diverse and evolving resistance mechanisms. For intensivists trained to treat the sickest patients with the broadest initial coverage, the perceived medico-legal and clinical risk of narrowing therapy on incomplete molecular information can outweigh the theoretical benefits, leading to what the correspondence implicitly identifies as the core failure mode: results that are available quickly but are not acted upon quickly.

Prior experience during the COVID-19 pandemic illustrates both the potential and the pitfalls. Novy and colleagues described an algorithm for the rational use of the FilmArray Pneumonia panel in bacterial coinfections of critically ill ventilated COVID-19 patients, published in Diagnostic Microbiology and Infectious Disease in 2021. Their work emphasized that the value of the panel depends on disciplined, protocolized interpretation rather than on the raw speed of the assay. Where such algorithms exist and are enforced, molecular results can meaningfully shape therapy; where they are absent, the same results risk becoming an expensive add-on that changes little at the bedside.

The Reims group is not a disinterested observer of this debate. The correspondence discloses that the corresponding author, Antoine Goury, is the coordinating investigator of the VAMPAIR trial, an ongoing randomized study registered with the French medicines agency ANSM under identifier 2024-A00908-39 and sponsored by CHU de Reims, which is evaluating multiplex PCR in ventilator-associated pneumonia. This positioning suggests that the correspondence is intended less as a rejection of molecular diagnostics than as a design brief for the next generation of studies: trials that measure decision latency, antibiotic duration, and patient-centered outcomes rather than turnaround time alone, and that build prespecified de-escalation rules directly into the diagnostic pathway.

The broader lesson for intensive care is that diagnostic innovation succeeds only when it is matched by therapeutic governance. Rapid syndromic PCR in ventilator-associated pneumonia can shorten the time to pathogen identification, support safe de-escalation in selected settings, and reduce unnecessary broad-spectrum exposure, but the randomized evidence to date shows that these benefits are contingent on workflow integration, clinician education, and honest accounting of the panels’ blind spots. As Goury and colleagues conclude, faster results are a necessary but not sufficient condition for faster decisions; closing the gap between the two is now the central challenge for molecular diagnostics in the ICU.

Subject of Research: Rapid molecular diagnostics and antibiotic decision-making in ventilator-associated pneumonia

Article Title: Rapid molecular diagnostics in VAP: when faster results do not mean faster decisions

Article References: Rapid molecular diagnostics in VAP: when faster results do not mean faster decisions. (n.d.). https://doi.org/10.1007/s00134-026-08631-y

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08631-y

Keywords: ventilator-associated pneumonia, multiplex PCR, rapid diagnostics, antibiotic stewardship, intensive care, de-escalation, resistance genes, FilmArray pneumonia panel, randomized controlled trial, ICU workflow, hospital-acquired pneumonia, molecular point-of-care testing